(CercleFinance.com) – The biopharmaceutical company Lysogene announced on Wednesday that it had been placed in receivership by the Commercial Court of Nanterre.
The gene therapy company, which specializes in diseases of the central nervous system, had been the subject of a safeguard procedure since last month.
In the absence of a solution to consolidate its financial situation and sustain its funding horizon, Lysogene had filed, with its legal administrator, a request with the Commercial Court of Nanterre to convert this safeguard procedure into a receivership procedure.
This request now approved, Lysogene recalls that a call for tenders for the purpose of finding buyers or investors has been published, with a deadline for submitting takeover offers set for February 15.